Clinical and metabolic response to probiotic administration in people with Parkinson's disease: A randomized, double-blind, placebo-controlled trial

Tamtaji, O.R. and Taghizadeh, M. and Daneshvar Kakhaki, R. and Kouchaki, E. and Bahmani, F. and Borzabadi, S. and Oryan, S. and Mafi, A. and Asemi, Z. (2018) Clinical and metabolic response to probiotic administration in people with Parkinson's disease: A randomized, double-blind, placebo-controlled trial. Clinical Nutrition.

[img] Text
1-s2.0-S0261561418302036-main.pdf

Download (282kB)
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....
DOI: UNSPECIFIED

Abstract

Background & aims: The investigation was done to assess the impacts of probiotic supplementation on movement and metabolic parameters in individuals with Parkinson's disease (PD). Methods: The study is randomized, double-blind, placebo-controlled clinical trial, which was done in sixty people with PD. Individuals were randomly divided into two groups in order to take either 8 � 109 CFU/day probiotic or placebo (n = 30 each group) that lasted 12 weeks. The Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) was recorded at pre- and post-intervention. Results: Compared with the placebo, consuming probiotic decreased MDS-UPDRS (�4.8 ± 12.5 vs. +3.8 ± 13.0, P = 0.01). Probiotic supplementation also reduced high-sensitivity C-reactive protein (�1.6 ± 2.5 vs. +0.1 ± 0.3 mg/L, P < 0.001) and malondialdehyde (�0.2 ± 0.3 vs. +0.1 ± 0.3 μmol/L, P = 0.006), and enhanced glutathione levels (+40.1 ± 81.5 vs. �12.1 ± 41.7 μmol/L, P = 0.03) in comparison with the placebo. Additionally, probiotic consumption resulted in a statistically significant reduction in insulin levels (�2.1 ± 3.4 vs. +1.5 ± 5.1 μIU/mL, P = 0.002) and insulin resistance (�0.5 ± 0.9 vs. +0.4 ± 1.2, P = 0.002), and a statistically significant rise in insulin sensitivity (+0.01 ± 0.02 vs. �0.006 ± 0.02, P = 0.01) in comparison with the placebo. Probiotic intake had no any significant impact on other metabolic profiles. Conclusions: Our study evidenced that 12 weeks of probiotic consumption by individuals with PD had useful impacts on MDS-UPDRS and few metabolic profiles. Registered under ClinicalTrials.gov Identifier no. http://www.irct.ir: IRCT2017082434497N4. © 2018 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism

Item Type: Article
Additional Information: cited By 5; Article in Press
Subjects: Psychology
Nutrition
Biochemistry, Genetics and Molecular Biology
Divisions: Faculty of Medicine > Basic Sciences > Department of Nutrition
Depositing User: ART . editor
Date Deposited: 13 Apr 2019 09:30
Last Modified: 13 Apr 2019 09:30
URI: http://eprints.kaums.ac.ir/id/eprint/4065

Actions (login required)

View Item View Item